Ask My Investor AI
Public company · London Stock Exchange (primary listing); New York Stock Exchange (US line); Nasdaq StockholmPublished company research
AZN

Identity cross-checked across SEC EDGAR (AstraZeneca PLC, CIK 0000901832, a UK foreign private issuer that files Form 20-F; FY2025 20-F filed Feb 2026, Commission file 001-11960, incorporated in England, registered office Cambridge, UK), the company's official FY2025 RNS final-results announcement (fetched via Investegate), and market data (Yahoo: NYSE, USD, AZN). Correction to the seed's 'NYSE/Nasdaq' hint: the US venue is the New York Stock Exchange - AstraZeneca completed a direct listing of its ordinary shares on the NYSE on 2 February 2026, superseding the former Nasdaq-listed ADRs; the primary/premium listing remains the London Stock Exchange (FTSE 100) and shares are also listed on Nasdaq Stockholm, all under ticker AZN. Caveat: sec.gov and astrazeneca.com pages returned HTTP 403 to the automated fetch tool, so SEC/issuer contents were corroborated via EDGAR search metadata and the fetched RNS announcement rather than rendered directly.

AstraZeneca PLC

AstraZeneca is a diversified global biopharmaceutical company that reported Q1 2026 total revenue of $15.288 billion, reported operating profit of $4.246 billion and operating cash inflow of $3.359 billion. Its Medical Isotopes exposure is a pre-commercial radioconjugate platform within Fusion Pharmaceuticals, including Phase 2 FPI-2265 and early-stage FPI-1434, FPI-2059 and FPI-2068. The platform is real but financially unquantified, so the subject remains NOT_READY for theme acceptance.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
AZN
Exchange
London Stock Exchange (primary listing); New York Stock Exchange (US line); Nasdaq Stockholm
HQ
United Kingdom
Currency
USD
SEC CIK
0000901832
Investment case

How this company captures the theme economics

Competitive position

AstraZeneca has global oncology development and commercialization scale, while Fusion supplies an alpha-emitting radioconjugate platform and dedicated technical capability. Current official disclosures place FPI-2265 in Phase 2 and the other named Fusion assets in Phase 1. No approved radioconjugate product or standalone radiopharma economics are disclosed.

Scarce assets

Scaled global R&D (core R&D ~24% of revenue), large-molecule and small-molecule engineering, worldwide manufacturing and commercial reach, and high-value oncology franchises and alliances (notably Enhertu with Daiichi Sankyo). For the medical-isotopes theme, the key scarce asset is the actinium-225 supply chain and radioconjugate manufacturing capability acquired with Fusion - actinium-225 is a genuinely supply-constrained alpha-emitting isotope with limited global production.

Products, segments, and customers

AstraZeneca reports across Oncology, BioPharmaceuticals and Rare Disease. Q1 2026 total revenue was $15.288 billion. Fusion's radioconjugate portfolio includes Phase 2 FPI-2265 for PSMA-positive metastatic castration-resistant prostate cancer and Phase 1 FPI-1434, FPI-2059 and FPI-2068.

Theme capture

AstraZeneca captures the theme through Fusion Pharmaceuticals, an AstraZeneca Group company developing alpha-emitting radioconjugates. The exposure is clinical-stage R&D and manufacturing capability, not a disclosed revenue segment; direct financial materiality and current valuation contribution cannot be established.

Conditions

What must be true

  1. Core oncology and newer launch franchises must keep compounding at high-single-digit-plus rates to sustain the company's stated multi-year growth trajectory and offset upcoming loss-of-exclusivity events.
  2. The radioconjugate pipeline (FPI-2265, FPI-2068) must produce positive mid/late-stage clinical data, and the acquired actinium-225 supply chain must scale, for the medical-isotope platform to become commercially material.
  3. Alliance-dependent assets (e.g., Enhertu with Daiichi Sankyo) must continue to perform and the company must manage US and China pricing/regulatory pressure without material margin erosion.

Identifiable catalysts

  • Phase II/III readouts for FPI-2265 in metastatic castration-resistant prostate cancer and progression toward pivotal trials.
  • Broader oncology pipeline data readouts and regulatory approvals across 2026-2027.
  • Full-year 2026 results and any updated pipeline/manufacturing disclosures on the radioconjugate platform.
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Radiopharmaceutical / radioconjugate drug developer that also owns scarce upstream isotope (actinium-225) supply and manufacturing capability - i.e., a downstream therapeutic developer vertically integrated into isotope logistics.

Medical isotopes and radiopharmaceutical logistics

Real but pre-commercial and financially unquantified. Current official AstraZeneca materials identify Fusion as a Group company and list FPI-2265 in Phase 2 plus FPI-1434, FPI-2059 and FPI-2068 in Phase 1. No commercial radioconjugate product or radiopharma revenue line is disclosed.

Evidence
AstraZeneca's SEC-filed Q1 2026 results directly establish group financial scale. Current AstraZeneca recruiting disclosures directly establish Fusion ownership and the named clinical portfolio, but do not disclose radioconjugate revenue, margin, isotope capacity or valuation contribution.
Materiality
not assessed — The operating capability is directly disclosed, but theme-specific financial materiality cannot be measured because radioconjugates remain clinical-stage and are not separately reported.
Financial evidence

Official public disclosures

Reference period: Q1 2026.

  • Total revenue$15,288 million, up 8% at constant exchange rates
    Q1 2026[1]
  • Reported operating profit$4,246 million
    Q1 2026[1]
  • Reported EPS$1.99
    Q1 2026[1]
  • Net cash inflow from operating activities$3,359 million
    Q1 2026[1]
  • Net debt$25,944 million
    March 31, 2026[1]
  • Cash and cash equivalents$7,560 million
    March 31, 2026[1]

Limitation: SEC-filed Q1 2026 results establish group financial scale and balance-sheet context. No radioconjugate revenue, profit, capital allocation or isotope-capacity line is disclosed, and licensed current valuation is unavailable.

Risks

Material risks and break conditions

Material risks

  • Loss of exclusivity and patent cliffs on major products, plus pricing pressure from the US Inflation Reduction Act drug-price negotiation and international reference pricing, which could compress revenue growth and margins.
  • Pipeline/clinical risk: the radioconjugate assets (FPI-2265, FPI-2068) are early-to-mid stage and may fail; the actinium-225 isotope is globally supply-constrained, which could limit the platform's ability to scale even if trials succeed.
  • Geopolitical and regulatory exposure in China (a material market for AstraZeneca) and dependence on key alliances (e.g., Enhertu with Daiichi Sankyo) and on continued M&A/integration execution.

Thesis-break conditions

  • FPI-2265 fails its pivotal/registrational endpoint or the actinium-225 supply cannot be scaled, stalling the radiopharmaceutical platform and removing the medical-isotope optionality.
  • Total revenue growth decelerates below mid-single digits or core oncology franchises decline due to loss-of-exclusivity or competition, breaking the compounding-growth trajectory.
  • Reported operating margin compresses materially or core EPS turns down year-on-year, contradicting the FY2025 uptrend (core EPS $9.16 vs $8.18).
Investability conclusion

Where the evidence lands

AstraZeneca presents as a large-cap, diversified, oncology-led biopharmaceutical company with strong FY2025 fundamentals (revenue $58,739m, reported operating profit $13,743m, operating cash inflow $14,575m) and a deep late-stage pipeline. The medical-isotopes / radiopharmaceutical theme is a genuine but currently immaterial, pre-commercial optionality delivered through the actinium-225 radioconjugate platform (Fusion) - a call option on future clinical and supply-chain success, not a present earnings driver. The overall investment case rests on sustained oncology growth and pipeline delivery against loss-of-exclusivity and pricing headwinds. This is an evidence summary, not investment advice; a full valuation assessment requires licensed market data not available in this session.

Next diligence

  1. Obtain the FY2025 Form 20-F financial statements and balance sheet directly from SEC EDGAR / issuer IR (net debt, total equity, cash) to complete the financial picture that the fetch tool could not render.
  2. Track FPI-2265 and FPI-2068 clinical-trial registries (ClinicalTrials.gov) and monitor Phase II/III readouts; assess actinium-225 supply agreements, production capacity and logistics constraints.
  3. Quantify the loss-of-exclusivity timeline for top products and model IRA/price-negotiation and China regulatory exposure.
  4. Confirm current market valuation multiples and consensus estimates via licensed market data.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. AstraZeneca results: Q1 2026, Form 6-KAstraZeneca PLC / U.S. Securities and Exchange Commission · primary · published 2026-04-29 · accessed 2026-07-29
  2. Fusion Pharmaceuticals clinical portfolio within AstraZeneca GroupAstraZeneca PLC · primary · published 2026-07-15 · accessed 2026-07-29
  3. AstraZeneca PLC - FY and Q4 2025 final results announcement (RNS)AstraZeneca PLC (RNS), via Investegate · primary · published 2026-02 · accessed 2026-07-22
  4. AstraZeneca results: FY and Q4 2025BioSpace (AstraZeneca press release) · secondary · published 2026-02 · accessed 2026-07-22
  5. AstraZeneca PLC - Form 20-F for the year ended 31 December 2025 (CIK 0000901832)U.S. Securities and Exchange Commission (EDGAR) / AstraZeneca PLC · primary · published 2026-02-24 · accessed 2026-07-22
  6. Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat CancerAstraZeneca / PR Newswire · primary · published 2024-03-19 · accessed 2026-07-22
  7. AstraZeneca completes Fusion Pharmaceuticals acquisitionPharmaceutical Technology · secondary · published 2024-06-05 · accessed 2026-07-22
  8. AstraZeneca Acquires Fusion for $2B in Radioconjugate Cancer DealInside Precision Medicine · secondary · published 2024-03 · accessed 2026-07-22
  9. AstraZeneca PLC (AZN) Stock Quote - NYSE, USDYahoo Finance · secondary · published 2026-07-22 · accessed 2026-07-22